Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00137774

Enrollment

Registered

2005-08-30

Start date

2004-11-30

Completion date

2012-12-31

Last updated

2013-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumors

Keywords

Metastatic Neuroendocrine Tumor, Advanced Neuroendocrine tumor, Bevacizumab, Temozolomide

Brief summary

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

Detailed description

Patients will receive temozolomide orally once daily for one week, followed by a one-week rest period. This one-week on/one week off schedule will continue for the duration of treatment unless significant side effects develop. Bevacizumab will be administered intravenously every other week. After eight weeks (two cycles), a CT scan will be performed to see how treatment affected tumor growth. Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help prevent infection. Blood tests will be done every other week to evaluate any side effects. Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan will be performed. Patients will remain on the study as long as they continue to receive benefit from the treatment and there are no serious side effects.

Interventions

DRUGBevacizumab

Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.

DRUGTemozolomide

Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically documented locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma * Measurable disease \> 1cm by spiral computed tomography (CT) or \> 2cm by other radiographic technique * ECOG performance status of 0-2 * Life expectancy of \> 12 weeks * Prior treatment with chemotherapy is allowed * Total bilirubin \< 2.0mg/dl * AST \< 5x upper limit of normal (ULN) * Serum creatinine \< 2.0mg/dl * Absolute neutrophil count \> 1,000/mm3 * Platelets \> 100,000/mm3 * International Normalized Ratio (INR) \< 1.5

Exclusion criteria

* Prior treatment with temozolomide, decarbazine or bevacizumab * Clinically apparent central nervous system metastases or carcinomatous meningitis * Clinically significant cardiovascular disease * Major surgery, open biopsy, or significant traumatic injury within 28 days * Pregnant or breast-feeding women * Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medication * Serious, nonhealing wound, ulcer or bone fracture * Evidence of bleeding diathesis or coagulopathy * History of other disease or metabolic dysfunction

Design outcomes

Primary

Measure	Time frame
To assess the response to bevacizumab in combination with temozolomide in patients with metastatic neuroendocrine tumors	2 years

Secondary

Measure	Time frame
To assess the time to progression, progression free survival and safety of bevacizumab in combination with temozolomide in this patient population	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026